keyword
MENU ▼
Read by QxMD icon Read
search

Brilique

keyword
https://www.readbyqxmd.com/read/25896573/prasugrel-efient%C3%A2-with-percutaneous-coronary-intervention-for-treating-acute-coronary-syndromes-review-of-ta182-systematic-review-and-economic-analysis
#1
REVIEW
Janette Greenhalgh, Adrian Bagust, Angela Boland, Kerry Dwan, Sophie Beale, Nigel Fleeman, Joanne McEntee, Yenal Dundar, Marty Richardson, Michael Fisher
BACKGROUND: Acute coronary syndromes (ACSs) are life-threatening conditions associated with acute myocardial ischaemia. There are three main types of ACS: ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI) and unstable angina (UA). One treatment for ACS is percutaneous coronary intervention (PCI) plus adjunctive treatment with antiplatelet drugs. Dual therapy antiplatelet treatment [aspirin plus either prasugrel (Efient(®), Daiichi Sankyo Company Ltd UK/Eli Lilly and Company Ltd), clopidogrel or ticagrelor (Brilique(®), AstraZeneca)] is standard in UK clinical practice...
April 2015: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/25672642/ticagrelor-a-review-of-its-use-in-adults-with-acute-coronary-syndromes
#2
REVIEW
Sohita Dhillon
Ticagrelor (Brilique™, Brilinta®), a cyclopentyl-triazolopyrimidine, is an orally active, reversible, and selective adenosine diphosphate (ADP) receptor antagonist indicated for use in patients with acute coronary syndromes (ACS). Ticagrelor has a faster onset of action and provides greater inhibition of platelet aggregation than clopidogrel. In the large well-designed, PLATO study in adult patients with ACS, 12 months' treatment with ticagrelor was more effective than clopidogrel in reducing the incidence of the primary composite endpoint of myocardial infarction, stroke, or cardiovascular (CV) death...
February 2015: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/24420365/perioperative-outcomes-of-cardiac-surgery-patients-with-ongoing-ticagrelor-therapy-boon-and-bane-of-a-new-drug
#3
Hanna Schotola, Anselm Bräuer, Katharina Meyer, José Hinz, Friedrich Albert Schöndube, Martin Bauer, Prashant Nanasaheb Mohite, Bernd Christoph Danner, Samuel Sossalla, Aron Frederik Popov
OBJECTIVES: Ticagrelor (Brilique®) is a novel reversible platelet inhibitor at P2Y12 receptor used in patients with acute coronary syndrome and patients undergoing percutaneous coronary interventions. Unlike clopidogrel (Plavix®), ticagrelor has a quicker offset of action, and therefore, it seems that platelet function recovers faster on discontinuation of therapy. These drugs sometimes cannot be stopped before coronary artery bypass grafting due to the risk of stent thrombosis or in case of emergency operations...
August 2014: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/23117664/-platelet-inhibitors-in-clinical-practice
#4
REVIEW
C Gebhard, J Beer
Despite improvements in the treatment of acute coronary syndromes, cardiovascular disease remains the leading cause of death in Europe and the United States. Antiplatelet agents, such as aspirin and clopidogrel, play an important role in the treatment of those patients. Several new alternatives have been tested in clinical trails and some of them have been approved for routine treatment of patients with ACS in Switzerland and the European Union. The latter include Prasugrel (Efient®) and Ticagrelor (Brilique®)...
November 2012: Therapeutische Umschau. Revue Thérapeutique
https://www.readbyqxmd.com/read/23115850/-medication-of-the-month-ticagrelor-brilique-potent-oral-antagonist-of-platelet-activity
#5
P Lancellotti
Dual antiplatelet therapy with clopidogrel combined with aspirin reduces ischemic events in acute coronary syndromes (ACS). The individual response to clopidogrel is, however, very variable from one subject to another, and the risk of events seems higher when platelet inhibition is insufficient. Ticagrelor is a potent oral inhibitor of platelet activity. It binds reversibly to the P2Y12 adenosine diphosphate. The platelet inhibition that it induces is faster and more pronounced than that of clopidogrel. In patients who have an ACS (PLATO study) with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke, without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding...
September 2012: Revue Médicale de Liège
https://www.readbyqxmd.com/read/22739809/antiplatelet-therapy-ticagrelor
#6
E Giannitsis, H A Katus
UNLABELLED: Ticagrelor, a cyclopentyltriazolopyrimidine (CPTP), is the representative of a new chemical class of P2Y(12) receptor inhibitors that differ from thienopyridines (ticlopidin, clopidogrel, prasugrel) as ticagrelor is not a prodrug requiring active biotransformation by cytochromes in the liver and thus is characterized by a more rapid, more effective and more consistent platelet inhibition than ticlopidin or clopidogrel. An extensive study program for dose finding and safety for AZD6140 (DISPERSE studies) and a large-scaled phase III trial (PLATO) were undertaken on more than 18,000 patients for validation of efficacy and safety...
2012: Hämostaseologie
https://www.readbyqxmd.com/read/22697589/ticagrelor-a-p2y12-antagonist-for-use-in-acute-coronary-syndromes
#7
REVIEW
Yanushi Dullewe Wijeyeratne, Rashi Joshi, Stan Heptinstall
Agents that inhibit platelet function are used routinely in the treatment and prevention of acute coronary syndromes. The main antiplatelet treatments used combine aspirin with one of the thienopyridine P2Y(12) antagonists, either clopidogrel or prasugrel. By blocking the synthesis of thromboxane A(2) in platelets and by blocking the effects of ADP, respectively, these agents reduce platelet activity, platelet aggregation and thrombus formation. Ticagrelor (marketed by AstraZeneca as Brilinta™ in the USA, and as Brilique(®) or Possia(®) in Europe) is a cyclopentyl-triazolo-pyrimidine, a new chemical class of P2Y(12) antagonist that is now approved for use in the wide spectrum of acute coronary syndromes...
May 2012: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/21632607/ticagrelor-for-acute-coronary-syndrome
#8
REVIEW
(no author information available yet)
Current guidelines from the National Institute for Clinical Excellence (NICE) recommend antiplatelet therapy comprising aspirin plus either clopidogrel or prasugrel for patients with acute coronary syndrome (ACS). However, such dual therapy increases the likelihood of bleeding compared to that with aspirin alone. Ticagrelor (Brilique - Astra-Zeneca) is a new oral antiplatelet drug recently licensed in the UK (since publication of the NICE guidelines) for use with aspirin in patients with ACS, including those managed medically or undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)...
June 2011: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/21568367/ticagrelor-a-review-of-its-use-in-the-management-of-acute-coronary-syndromes
#9
REVIEW
Emma D Deeks
Ticagrelor (Brilique™; Brilinta™), a cyclopentyl-triazolo-pyrimidine antiplatelet agent, is the first oral antagonist of the P2Y(12) receptor to offer reversible receptor binding. It is indicated in the EU for the prevention of atherothrombotic events in adults with acute coronary syndromes (ACS) [unstable angina pectoris, ST-segment elevation myocardial infarction [STEMI] or non-STEMI), including those managed medically or with percutaneous coronary intervention or coronary artery bypass grafting (CABG)...
May 7, 2011: Drugs
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"